JP2024096905A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024096905A5 JP2024096905A5 JP2024066115A JP2024066115A JP2024096905A5 JP 2024096905 A5 JP2024096905 A5 JP 2024096905A5 JP 2024066115 A JP2024066115 A JP 2024066115A JP 2024066115 A JP2024066115 A JP 2024066115A JP 2024096905 A5 JP2024096905 A5 JP 2024096905A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- combination
- drug
- pharmaceutical
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17174169 | 2017-06-02 | ||
| EP17174169.7 | 2017-06-02 | ||
| PCT/EP2018/063785 WO2018219807A1 (en) | 2017-06-02 | 2018-05-25 | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
| JP2019565949A JP7303122B2 (ja) | 2017-06-02 | 2018-05-25 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
| JP2022138972A JP7475402B2 (ja) | 2017-06-02 | 2022-09-01 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022138972A Division JP7475402B2 (ja) | 2017-06-02 | 2022-09-01 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024096905A JP2024096905A (ja) | 2024-07-17 |
| JP2024096905A5 true JP2024096905A5 (https=) | 2024-08-20 |
| JP7806119B2 JP7806119B2 (ja) | 2026-01-26 |
Family
ID=58992733
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565949A Active JP7303122B2 (ja) | 2017-06-02 | 2018-05-25 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
| JP2022138972A Active JP7475402B2 (ja) | 2017-06-02 | 2022-09-01 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
| JP2024066115A Active JP7806119B2 (ja) | 2017-06-02 | 2024-04-16 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019565949A Active JP7303122B2 (ja) | 2017-06-02 | 2018-05-25 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
| JP2022138972A Active JP7475402B2 (ja) | 2017-06-02 | 2022-09-01 | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US11951166B2 (https=) |
| EP (2) | EP4342542A3 (https=) |
| JP (3) | JP7303122B2 (https=) |
| KR (2) | KR102843438B1 (https=) |
| CN (3) | CN117582495A (https=) |
| AU (2) | AU2018276273B2 (https=) |
| BR (1) | BR112019025478A8 (https=) |
| CA (2) | CA3244313A1 (https=) |
| DK (1) | DK3630112T3 (https=) |
| ES (1) | ES2978337T3 (https=) |
| FI (1) | FI3630112T3 (https=) |
| HR (1) | HRP20240551T1 (https=) |
| HU (1) | HUE066487T2 (https=) |
| IL (2) | IL317015A (https=) |
| LT (1) | LT3630112T (https=) |
| MX (1) | MX2023001721A (https=) |
| PE (2) | PE20200859A1 (https=) |
| PL (1) | PL3630112T3 (https=) |
| PT (1) | PT3630112T (https=) |
| RS (1) | RS65488B9 (https=) |
| SI (1) | SI3630112T1 (https=) |
| WO (1) | WO2018219807A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3244313A1 (en) * | 2017-06-02 | 2025-06-13 | Bayer Healthcare Llc | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
| CN111001004A (zh) * | 2019-10-08 | 2020-04-14 | 广州医科大学附属第二医院 | 一种治疗肝癌的药物组合及其应用 |
| TW202539722A (zh) * | 2023-12-01 | 2025-10-16 | 耶魯大學 | 治療癌症的組合物和方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1663978B1 (en) | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| EP1948144A2 (en) | 2005-11-10 | 2008-07-30 | Bayer HealthCare AG | Diaryl urea for treating diabetic neuropathy |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
| AR092439A1 (es) * | 2012-09-06 | 2015-04-22 | Bayer Healthcare Llc | Composicion farmaceutica recubierta que contiene regorafenib |
| EP2900269B1 (en) * | 2012-09-25 | 2018-08-01 | Bayer Pharma Aktiengesellschaft | Combination of regorafenib and acetylsalicylic acid for treating colorectal cancer |
| JP5653489B1 (ja) | 2013-07-24 | 2015-01-14 | 三菱エンジニアリングプラスチックス株式会社 | 薄肉光学部材用ポリカーボネート樹脂ペレット及びその製造方法 |
| PL3102605T3 (pl) | 2014-02-04 | 2019-06-28 | Pfizer Inc. | Połączenie antagonisty pd-1 i inhibitora vegfr do leczenia nowotworu |
| WO2015125652A1 (ja) | 2014-02-21 | 2015-08-27 | Ｉｄａｃセラノスティクス株式会社 | 固形がんの治療剤 |
| EP3563870A1 (en) | 2014-07-15 | 2019-11-06 | F. Hoffmann-La Roche AG | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| JP6626085B2 (ja) | 2014-07-15 | 2019-12-25 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法 |
| US10392444B2 (en) * | 2014-08-08 | 2019-08-27 | Oncoquest, Inc. | Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer |
| KR20170042778A (ko) * | 2014-08-19 | 2017-04-19 | 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 | 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법 |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| KR20230030022A (ko) | 2014-11-13 | 2023-03-03 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
| WO2016173959A1 (en) * | 2015-04-28 | 2016-11-03 | Bayer Pharma Aktiengesellschaft | Regorafenib for treating colorectal cancer |
| WO2017046746A1 (en) | 2015-09-15 | 2017-03-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist |
| WO2017210119A1 (en) | 2016-06-03 | 2017-12-07 | Imclone Llc | Combination of ramucirumab and pembrolizumab for the treatment of certain cancers |
| US10251888B2 (en) | 2016-06-13 | 2019-04-09 | Chemocentryx, Inc. | Method of treating pancreatic cancer |
| CA3244313A1 (en) * | 2017-06-02 | 2025-06-13 | Bayer Healthcare Llc | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
| CR20190550A (es) * | 2017-06-05 | 2020-04-05 | Janssen Biotech Inc | Anticuerpos que se unen específicamente a pd-1 y métodos de uso |
-
2018
- 2018-05-25 CA CA3244313A patent/CA3244313A1/en active Pending
- 2018-05-25 LT LTEPPCT/EP2018/063785T patent/LT3630112T/lt unknown
- 2018-05-25 HU HUE18725258A patent/HUE066487T2/hu unknown
- 2018-05-25 CN CN202311446796.9A patent/CN117582495A/zh active Pending
- 2018-05-25 PE PE2019002499A patent/PE20200859A1/es unknown
- 2018-05-25 WO PCT/EP2018/063785 patent/WO2018219807A1/en not_active Ceased
- 2018-05-25 DK DK18725258.0T patent/DK3630112T3/da active
- 2018-05-25 JP JP2019565949A patent/JP7303122B2/ja active Active
- 2018-05-25 IL IL317015A patent/IL317015A/en unknown
- 2018-05-25 CN CN201880036504.5A patent/CN110662540B/zh active Active
- 2018-05-25 FI FIEP18725258.0T patent/FI3630112T3/fi active
- 2018-05-25 EP EP24150061.0A patent/EP4342542A3/en active Pending
- 2018-05-25 KR KR1020247017968A patent/KR102843438B1/ko active Active
- 2018-05-25 PT PT187252580T patent/PT3630112T/pt unknown
- 2018-05-25 ES ES18725258T patent/ES2978337T3/es active Active
- 2018-05-25 PE PE2024001939A patent/PE20242220A1/es unknown
- 2018-05-25 HR HRP20240551TT patent/HRP20240551T1/hr unknown
- 2018-05-25 CN CN202410088226.5A patent/CN117899212A/zh active Pending
- 2018-05-25 US US16/617,642 patent/US11951166B2/en active Active
- 2018-05-25 EP EP18725258.0A patent/EP3630112B9/en active Active
- 2018-05-25 SI SI201831091T patent/SI3630112T1/sl unknown
- 2018-05-25 BR BR112019025478A patent/BR112019025478A8/pt not_active Application Discontinuation
- 2018-05-25 PL PL18725258.0T patent/PL3630112T3/pl unknown
- 2018-05-25 AU AU2018276273A patent/AU2018276273B2/en active Active
- 2018-05-25 KR KR1020197038281A patent/KR102673422B1/ko active Active
- 2018-05-25 CA CA3065125A patent/CA3065125C/en active Active
- 2018-05-25 IL IL270948A patent/IL270948B2/en unknown
- 2018-05-25 RS RS20240481A patent/RS65488B9/sr unknown
-
2019
- 2019-12-02 MX MX2023001721A patent/MX2023001721A/es unknown
- 2019-12-31 US US16/731,412 patent/US11517622B2/en active Active
- 2019-12-31 US US16/731,409 patent/US20200155674A1/en not_active Abandoned
-
2022
- 2022-01-14 US US17/576,522 patent/US20220133888A1/en active Pending
- 2022-09-01 JP JP2022138972A patent/JP7475402B2/ja active Active
-
2023
- 2023-12-12 AU AU2023282197A patent/AU2023282197B2/en active Active
-
2024
- 2024-04-16 JP JP2024066115A patent/JP7806119B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024096905A5 (https=) | ||
| JP2022169780A5 (https=) | ||
| ES2800026T3 (es) | Tratamiento de enfermedades inmunitarias e inflamatorias | |
| JP2020511414A5 (https=) | ||
| JP2020513745A5 (https=) | ||
| JP2016528162A5 (https=) | ||
| JP2016515628A5 (https=) | ||
| CN117599029A (zh) | 用于控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物 | |
| CN105001165A (zh) | 取代的二氨基嘧啶其组合物，和用其治疗的方法 | |
| JP2020117511A (ja) | 過敏性腸症候群および末梢神経系の他の病気の治療のための末梢限局性ｇａｂａポジティブアロステリックモジュレーター | |
| JP2013520971A5 (https=) | ||
| HRP20120323T4 (hr) | Spoj diaril-hidantoina | |
| JP2021513536A5 (https=) | ||
| JP2015500702A5 (https=) | ||
| JP2018533560A5 (https=) | ||
| CA3083228A1 (en) | Small molecule degraders that recruit dcaft15 | |
| JP2013527224A5 (https=) | ||
| CN105218532B (zh) | 苯并三氮唑类化合物、制备方法和其医药用途 | |
| JP2017516827A5 (https=) | ||
| JP2008500277A5 (https=) | ||
| JP2020521786A5 (https=) | ||
| FI3630112T3 (fi) | Regorafenibin ja nivolumabin yhdistelmä syövän hoidossa | |
| JP2017536397A5 (https=) | ||
| EA200700158A1 (ru) | Лекарственные формы с ядром таблетки, покрытым энтеросолюбильной оболочкой | |
| JP2024541900A5 (https=) |